We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
154 hedge funds and large institutions have $547M invested in AbCellera Biologics in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 46 increasing their positions, 43 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
8% more funds holding
Funds holding: 142 → 154 (+12)
7% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 43
0.14% more ownership
Funds ownership: 41.15% → 41.3% (+0.14%)
20% less capital invested
Capital invested by funds: $682M → $547M (-$136M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
32% less call options, than puts
Call options by funds: $1.82M | Put options by funds: $2.68M
Holders
154
Holders Change
+12
Holders Change %
+8.45%
% of All Funds
2.22%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
27
Increased
46
Reduced
43
Closed
14
Calls
$1.82M
Puts
$2.68M
Net Calls
-$857K
Net Calls Change
-$5.65M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$23.6M |
| 2 |
Man Group
London,
United Kingdom
|
+$3.94M |
| 3 |
Two Sigma Advisers
New York
|
+$3.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.16M |
| 5 |
Two Sigma Investments
New York
|
+$2.1M |
Top Sellers
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$9.24M |
| 2 |
Lazard Asset Management
New York
|
-$7.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.41M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$3.77M |
| 5 |
Goldman Sachs
New York
|
-$2.01M |
